Johnson & Johnson Tests Prostate Cancer Drug JNJ-6143

Early trial data show most patients on the candidate saw a sharp drop in PSA levels, and Phase 2 testing is now underway.

Updated on Nov. 10, 2026 in Cancer

Johnson & Johnson Tests Prostate Cancer Drug JNJ-6143

Johnson & Johnson is developing JNJ-6143 for prostate cancer that continues to progress despite multiple treatments. In Phase 1 trials announced October 25, 77% of patients taking a daily 50 mg dose saw PSA levels fall by more than half.

Why it matters

Most existing prostate cancer drugs block male hormone production or action, and resistance can develop over time, leading to progression. Global drugmakers are entering the field with new candidates aimed at patients who no longer respond to current options.

The Phase 1 results come from a small trial, with tumor measurements available for only 16 patients, of whom 12 showed shrinkage or disappearance. Whether these early responses will hold in larger Phase 2 testing remains unknown.

The players

Johnson & Johnson

A large American multinational pharmaceutical and medical device company that is developing JNJ-6143.

The details

JNJ-6143 forces the androgen receptor to bind with BRD4, disrupting BRD4's function and triggering cancer cell death. The company is currently conducting Phase 2 trials to assess the candidate further.

Timeline

  1. October 25: Johnson & Johnson announced Phase 1 results for JNJ-6143.

  2. Phase 2 clinical trials for JNJ-6143 are currently underway.

Market Landscape

Global prostate cancer treatment was estimated at about $19.1 billion in 2025, and GSK's antibody-drug conjugate GSK5764227 is in Phase 3 trials. Pharmaceutical companies are racing to develop next-generation options for patients whose disease progresses on existing drugs.

Patients with prostate cancer that progresses despite current treatments may one day have access to new drug options if trials succeed. Any new therapy would still need to clear Phase 2 testing and regulatory review before becoming available.

The takeaway

Early results are promising but limited, and patients should speak with their oncologists about current and emerging treatment options.

Further reading

Explore more on Cancer research and treatment developments.

Source note: This article includes information reported by 조선일보.